JP2013533304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533304A5 JP2013533304A5 JP2013523659A JP2013523659A JP2013533304A5 JP 2013533304 A5 JP2013533304 A5 JP 2013533304A5 JP 2013523659 A JP2013523659 A JP 2013523659A JP 2013523659 A JP2013523659 A JP 2013523659A JP 2013533304 A5 JP2013533304 A5 JP 2013533304A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- lantibiotic
- type
- treatment
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 52
- 238000009472 formulation Methods 0.000 claims description 50
- 108010062877 Bacteriocins Proteins 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 235000014666 liquid concentrate Nutrition 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 229960003085 meticillin Drugs 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- ICIJWOWQUHHETJ-UHFFFAOYSA-N (3,5-dichlorophenyl)methanamine Chemical compound NCC1=CC(Cl)=CC(Cl)=C1 ICIJWOWQUHHETJ-UHFFFAOYSA-N 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 108010053762 deoxyactagardine B Proteins 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000008504 concentrate Nutrition 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000013020 final formulation Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1013513.5A GB201013513D0 (en) | 2010-08-11 | 2010-08-11 | Formulations |
| GB1013513.5 | 2010-08-11 | ||
| PCT/GB2011/001191 WO2012020219A2 (en) | 2010-08-11 | 2011-08-09 | Formulations for infusion of type b lantibiotics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533304A JP2013533304A (ja) | 2013-08-22 |
| JP2013533304A5 true JP2013533304A5 (enExample) | 2014-09-18 |
| JP5865374B2 JP5865374B2 (ja) | 2016-02-17 |
Family
ID=42931511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523659A Expired - Fee Related JP5865374B2 (ja) | 2010-08-11 | 2011-08-09 | Ｂ型ランチビオティックの点滴用製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9192569B2 (enExample) |
| EP (1) | EP2603204A2 (enExample) |
| JP (1) | JP5865374B2 (enExample) |
| CN (1) | CN103108628B (enExample) |
| CA (1) | CA2807206A1 (enExample) |
| EA (1) | EA024344B1 (enExample) |
| GB (1) | GB201013513D0 (enExample) |
| MX (1) | MX2013001470A (enExample) |
| WO (1) | WO2012020219A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
| EP4092038A1 (en) | 2017-09-11 | 2022-11-23 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| CN109620979B (zh) * | 2018-12-29 | 2020-09-01 | 福建师范大学 | 低离子休克提高氨基糖苷类抗生素杀灭持留菌效率的方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1013513A (en) | 1963-03-25 | 1965-12-15 | Watney Combe Reid & Co Ltd | Improvements in and relating to hopping beer |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| GB8507528D0 (en) | 1985-03-22 | 1985-05-01 | Lepetit Spa | Basis monocarboxyamide derivatives |
| US5304540A (en) | 1988-06-22 | 1994-04-19 | Applied Microbiology, Inc. | Pharmaceutical bacteriocin compositions and methods for using the same |
| IN167138B (enExample) | 1988-08-17 | 1990-09-01 | Hoechst India | |
| GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| IT1260505B (it) | 1992-06-01 | 1996-04-09 | Poli Ind Chimica Spa | Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon |
| IL107887A (en) | 1992-12-08 | 2003-07-06 | Ambi Inc | Stabilized lanthionine containing bacteriocin compositions |
| US5512269A (en) | 1993-06-09 | 1996-04-30 | Burroughs Wellcome, Co. | Method of treating retained pulmonary secretions |
| ATE255165T1 (de) | 1994-09-12 | 2003-12-15 | Aventis Pharma Gmbh | Rekombinantes mersacidin und verfahren zu seiner herstellung |
| DE69629691T2 (de) | 1995-06-23 | 2004-02-26 | Ambi, Inc. | Verfahren zur kontrolle von antibiotikaresistenten grampositiven bakterien und behandlung von infektionen |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US5958873A (en) | 1997-06-09 | 1999-09-28 | University Of Cincinnati | Oral formulation for treatment of bacteria-induced diseases of the colon |
| US5985823A (en) | 1997-06-09 | 1999-11-16 | Ambi Inc. | Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon |
| DE19745583A1 (de) | 1997-10-15 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben |
| US6569830B1 (en) | 1999-03-05 | 2003-05-27 | Ambi, Inc. | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| KR20030017569A (ko) | 2000-06-28 | 2003-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 카르베딜올 |
| GB0110432D0 (en) | 2001-04-27 | 2001-06-20 | Plant Bioscience Ltd | Lantibiotic production |
| WO2002103010A1 (en) | 2001-06-14 | 2002-12-27 | Plant Bioscience Limited | Methods and materials for targeted gene disruption in actinomycete bacteria |
| US6861236B2 (en) | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
| US7199230B2 (en) | 2002-10-10 | 2007-04-03 | Molichem Medicines, Inc. | Nucleic acids encoding duramycin |
| EP1560540A4 (en) * | 2002-10-18 | 2008-03-19 | Molichem Medicines Inc | METHOD FOR TREATING DRY EYES WITH LANTIBIOTICS |
| ATE356143T1 (de) | 2003-07-18 | 2007-03-15 | Vicuron Pharm Inc | Antibiotikum 107891, dessen faktoren a1 und a2, pharmazeutisch unbedenkliche salze und zusammensetzungen, und anwendung davon |
| US7351687B2 (en) | 2003-07-18 | 2008-04-01 | Vicuron Pharmaceuticals, Inc. | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
| JP2007523092A (ja) | 2004-02-17 | 2007-08-16 | キャンサーバックス コーポレイション | 新脈管形成阻害のための方法および組成物 |
| GB0406870D0 (en) | 2004-03-26 | 2004-04-28 | Novacta Biosystems Ltd | Improvements relating to the production of lantibiotics |
| CA2623624A1 (en) | 2005-09-27 | 2007-04-05 | Novacta Biosystems Limited | Variants of the lantibiotic mersacidin and their use |
| GB0600928D0 (en) * | 2006-01-17 | 2006-02-22 | Novacta Biosystems Ltd | Improvements relating to lantibiotics |
| ES2744816T3 (es) | 2006-10-27 | 2020-02-26 | Capsugel Belgium Nv | Cápsulas duras de hidroxipropil metil celulosa y proceso de fabricación |
| US20110150917A1 (en) | 2007-06-12 | 2011-06-23 | The University Of British Columbia | Small Cationic Antimicrobial Peptides |
| GB0714030D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | The use of type-B lantibiotic-based compounds having antimicrobial activity |
| GB0714029D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | Lantibiotic-based compounds having antimicrobial activity |
| KR20110086582A (ko) | 2008-11-24 | 2011-07-28 | 센티넬라 파마세티컬즈, 인크. | 항균활성이 강화된 란티바이오틱 카르복시아미드 유도체 |
| GB0900599D0 (en) | 2009-01-14 | 2009-02-18 | Novacta Biosystems Ltd | Treatment |
| RS53586B1 (sr) * | 2009-01-14 | 2015-02-27 | Novacta Biosystems Limited | Derivati deoksiaktagardina |
| KR20110122139A (ko) | 2009-02-04 | 2011-11-09 | 노박타 바이오시스템스 리미티드 | 액타가르딘 유도체 |
| CA2789164A1 (en) | 2010-02-02 | 2011-08-11 | Novacta Biosystems Limited | Lantibiotic salts |
| GB201001688D0 (en) | 2010-02-02 | 2010-03-17 | Novacta Biosystems Ltd | Compounds |
| JP2013531026A (ja) | 2010-07-14 | 2013-08-01 | ノヴァクタ バイオシステムズ リミティッド | Ｂ型ランチビオティックを含む製剤 |
-
2010
- 2010-08-11 GB GBGB1013513.5A patent/GB201013513D0/en not_active Ceased
-
2011
- 2011-08-09 JP JP2013523659A patent/JP5865374B2/ja not_active Expired - Fee Related
- 2011-08-09 EP EP11749878.2A patent/EP2603204A2/en not_active Withdrawn
- 2011-08-09 EA EA201291463A patent/EA024344B1/ru not_active IP Right Cessation
- 2011-08-09 CA CA2807206A patent/CA2807206A1/en not_active Abandoned
- 2011-08-09 CN CN201180038723.5A patent/CN103108628B/zh not_active Expired - Fee Related
- 2011-08-09 US US13/816,063 patent/US9192569B2/en not_active Expired - Fee Related
- 2011-08-09 MX MX2013001470A patent/MX2013001470A/es not_active Application Discontinuation
- 2011-08-09 WO PCT/GB2011/001191 patent/WO2012020219A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI738632B (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| JP2015525763A5 (enExample) | ||
| RU2017131618A (ru) | Стабильный жидкий состав для моноклональных антител | |
| RU2015111341A (ru) | Композиции антитела и белка | |
| UA107211C2 (uk) | Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r) | |
| JP2018508572A (ja) | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 | |
| HRP20201268T1 (hr) | Stabilne formulacije koje sadrže anti-pcsk9 antitijela | |
| EA201492021A1 (ru) | Антительный состав | |
| JP2012515221A5 (enExample) | ||
| HRP20191199T1 (hr) | Formulacije protutijela anti-prolaktinskog receptora | |
| JP2019504086A5 (enExample) | ||
| JP2015231997A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| RU2013148537A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| JP7671125B2 (ja) | 免疫除去療法 | |
| JP2013511522A (ja) | ダプトマイシン製剤 | |
| CN105722852B (zh) | 用于治疗口腔粘膜炎的新型肽和类似物 | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| JP2013532729A5 (enExample) | ||
| EA201592279A1 (ru) | Фармацевтическая композиция, ее получение и применение | |
| JP2014526541A5 (enExample) | ||
| JP2013533304A5 (enExample) | ||
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 |